These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10792556)

  • 1. The EWA (estrogen in women with atherosclerosis) study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. Characteristics of the study population. Effects on lipids and lipoproteins.
    Os I; Hofstad AE; Brekke M; Abdelnoor M; Nesheim BI; Jacobsen AF; Birkeland K; Larsen A; Midtbo K; Westheim A
    J Intern Med; 2000 Apr; 247(4):433-41. PubMed ID: 10792556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins.
    Bhathena RK; Anklesaria BS; Ganatra AM; Pinto R
    Br J Clin Pharmacol; 1998 Feb; 45(2):170-2. PubMed ID: 9491833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine.
    Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A
    Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of transdermal 17 beta-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women.
    Słowińska-Srzednicka J; Zgliczyński S; Chotkowska E; Srzednicki M; Stopińska-Głuszak U; Jeske W; Brzezińska A; Zgliczyński W; Sadowski Z
    J Intern Med; 1993 Nov; 234(5):447-51. PubMed ID: 7693846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate.
    Lemay A; Dodin S; Cédrin I; T-Lemay L
    Clin Endocrinol (Oxf); 1995 Apr; 42(4):341-51. PubMed ID: 7750187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens.
    Taskinen MR; Puolakka J; Pyörälä T; Luotola H; Bjäörn M; Kääriänen J; Lahdenperä S; Ehnholm C
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1215-21. PubMed ID: 8857916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma leptin in postmenopausal women with coronary artery disease: effect of transdermal 17beta-estradiol and intermittent medroxyprogesterone acetate.
    Os I; Os A; Abdelnoor M; Larsen A; Birkeland K; Westheim A
    Climacteric; 2003 Sep; 6(3):204-10. PubMed ID: 14567768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
    Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
    J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the response of serum lipids and lipoproteins to postmenopausal hormone replacement therapy modified by ApoE genotype?
    Heikkinen AM; Niskanen L; Ryynänen M; Komulainen MH; Tuppurainen MT; Parviainen M; Saarikoski S
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):402-7. PubMed ID: 9974425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin sensitivity in women with coronary heart disease during hormone replacement therapy.
    Os I; Os A; Abdelnoor M; Larsen A; Birkeland K; Westheim A
    J Womens Health (Larchmt); 2005 Mar; 14(2):137-45. PubMed ID: 15775731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status.
    Lamon-Fava S; Herrington DM; Horvath KV; Schaefer EJ; Asztalos BF
    Metabolism; 2010 Dec; 59(12):1794-800. PubMed ID: 20580029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.
    Perrone G; Stefanutti C; Galoppi P; Anelli G; Capri O; Lucani G; Vivenzio A; Mazzarella B; Zichella L
    Int J Fertil Menopausal Stud; 1996; 41(6):509-15. PubMed ID: 9010744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
    van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins.
    Vadlamudi S; MacLean P; Israel RG; Marks RH; Hickey M; Otvos J; Barakat H
    Metabolism; 1998 Oct; 47(10):1222-6. PubMed ID: 9781625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.
    Hänggi W; Lippuner K; Riesen W; Jaeger P; Birkhäuser MH
    Br J Obstet Gynaecol; 1997 Jun; 104(6):708-17. PubMed ID: 9197875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
    Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
    Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.
    Waters DD; Alderman EL; Hsia J; Howard BV; Cobb FR; Rogers WJ; Ouyang P; Thompson P; Tardif JC; Higginson L; Bittner V; Steffes M; Gordon DJ; Proschan M; Younes N; Verter JI
    JAMA; 2002 Nov; 288(19):2432-40. PubMed ID: 12435256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.